BioCentury | Jan 16, 2020
Company News

Jan. 15 Company Quick Takes: Japan Tobacco gets rights to Dermavant therapy; plus Clovis, BMS, Recordati, BeiGene, Insilico-Pfizer, Novartis

...Japan Tobacco gets Japanese rights to Dermavant’s dermatology therapy Japan Tobacco Inc. (TOKYO:2914) licensed from Dermavant Sciences exclusive...
...#), BMS-734016 (Compound #), ipilimumab (Generic), Yervoy (Other) Insilico Medicine Inc. Pfizer Inc. NHS England Novartis AG EUSA Pharma Ltd. BeiGene Ltd. Japan Tobacco Inc. Roivant...
BioCentury | Oct 30, 2019
Preclinical News

Boehringer joins KRAS race with a molecule designed to block all mutations

...and in combination with approved MEK inhibitor Mekinist trametinib from Novartis AG (NYSE:NVS; SIX:NOVN) and Japan Tobacco Inc....
BioCentury | Oct 29, 2019

Combined inhibition of G12C-mutant KRAS, mTOR and IGF1R for NSCLC

...growth compared with either the G12C-mutant KRAS inhibitor alone or the linsitinib and Afinitor combo. Japan Tobacco Inc....
BioCentury | Apr 22, 2019
Distillery Therapeutics

TGFBR1 inhibition for GATA4-deficient lung cancer

...Next steps could include testing TGFBR1 inhibitors in combination with other therapies in PDX models. Japan Tobacco Inc....
BioCentury | Dec 4, 2018
Distillery Therapeutics

Infectious disease

...Next steps could include testing VEGF-A, VEGFR-2 and HIF1 inhibitors in other models of CDI. Japan Tobacco...
BioCentury | Nov 6, 2018
Distillery Therapeutics

Cancer

...alone. Next steps could include testing the safety of the inhibitor combination in the models. Japan Tobacco Inc....
...Mass. email: ahata@mgh.harvard.edu Alicia Parker AMG 176 Mekinist (Brand), GSK1120212 (Compound #), trametinib (Generic), Mekinist (Other), 1120212 (Other) Amgen Inc. Japan Tobacco Inc. Massachusetts...
BioCentury | Oct 25, 2018
Distillery Therapeutics

Neurology

...agonist decreased clinical seizure scores and increased survival. Next steps could include optimizing the compound. Japan Tobacco Inc....
BioCentury | Oct 20, 2018
Product Development

CVOT damage in diabetes

...Peptide Sanofi (Euronext:SAN; NYSE:SNY) Pyruvate dehydrogenase kinase (PDK) Glucose signaling pathway Unknown JTT-251 Small molecule Japan Tobacco Inc....
BioCentury | Oct 11, 2018
Distillery Therapeutics

Cancer

...and the Genentech Inc. unit of Roche market Zelboraf to treat unresectable or metastatic melanoma. Japan Tobacco Inc....
BioCentury | Sep 21, 2018
Tools & Techniques

Precision for pancreatic cancer

...targets, appearing in four patients. One person treated with the MAP2K1 inhibitor Mekinist trametinib from Japan Tobacco Inc....
...Ingelheim, Germany Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. Dana-Farber Cancer Institute, Boston, Mass. Japan Tobacco Inc....
Items per page:
1 - 10 of 376
BioCentury | Jan 16, 2020
Company News

Jan. 15 Company Quick Takes: Japan Tobacco gets rights to Dermavant therapy; plus Clovis, BMS, Recordati, BeiGene, Insilico-Pfizer, Novartis

...Japan Tobacco gets Japanese rights to Dermavant’s dermatology therapy Japan Tobacco Inc. (TOKYO:2914) licensed from Dermavant Sciences exclusive...
...#), BMS-734016 (Compound #), ipilimumab (Generic), Yervoy (Other) Insilico Medicine Inc. Pfizer Inc. NHS England Novartis AG EUSA Pharma Ltd. BeiGene Ltd. Japan Tobacco Inc. Roivant...
BioCentury | Oct 30, 2019
Preclinical News

Boehringer joins KRAS race with a molecule designed to block all mutations

...and in combination with approved MEK inhibitor Mekinist trametinib from Novartis AG (NYSE:NVS; SIX:NOVN) and Japan Tobacco Inc....
BioCentury | Oct 29, 2019

Combined inhibition of G12C-mutant KRAS, mTOR and IGF1R for NSCLC

...growth compared with either the G12C-mutant KRAS inhibitor alone or the linsitinib and Afinitor combo. Japan Tobacco Inc....
BioCentury | Apr 22, 2019
Distillery Therapeutics

TGFBR1 inhibition for GATA4-deficient lung cancer

...Next steps could include testing TGFBR1 inhibitors in combination with other therapies in PDX models. Japan Tobacco Inc....
BioCentury | Dec 4, 2018
Distillery Therapeutics

Infectious disease

...Next steps could include testing VEGF-A, VEGFR-2 and HIF1 inhibitors in other models of CDI. Japan Tobacco...
BioCentury | Nov 6, 2018
Distillery Therapeutics

Cancer

...alone. Next steps could include testing the safety of the inhibitor combination in the models. Japan Tobacco Inc....
...Mass. email: ahata@mgh.harvard.edu Alicia Parker AMG 176 Mekinist (Brand), GSK1120212 (Compound #), trametinib (Generic), Mekinist (Other), 1120212 (Other) Amgen Inc. Japan Tobacco Inc. Massachusetts...
BioCentury | Oct 25, 2018
Distillery Therapeutics

Neurology

...agonist decreased clinical seizure scores and increased survival. Next steps could include optimizing the compound. Japan Tobacco Inc....
BioCentury | Oct 20, 2018
Product Development

CVOT damage in diabetes

...Peptide Sanofi (Euronext:SAN; NYSE:SNY) Pyruvate dehydrogenase kinase (PDK) Glucose signaling pathway Unknown JTT-251 Small molecule Japan Tobacco Inc....
BioCentury | Oct 11, 2018
Distillery Therapeutics

Cancer

...and the Genentech Inc. unit of Roche market Zelboraf to treat unresectable or metastatic melanoma. Japan Tobacco Inc....
BioCentury | Sep 21, 2018
Tools & Techniques

Precision for pancreatic cancer

...targets, appearing in four patients. One person treated with the MAP2K1 inhibitor Mekinist trametinib from Japan Tobacco Inc....
...Ingelheim, Germany Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. Dana-Farber Cancer Institute, Boston, Mass. Japan Tobacco Inc....
Items per page:
1 - 10 of 376